EQS-Adhoc: M1 Kliniken AG: M1 Kliniken AG: HAEMATO AG sells its 100% subsidiary HAEMATO Pharm GmbH to PHOENIX group

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

M1 Kliniken AG: HAEMATO AG sells its 100% subsidiary HAEMATO Pharm GmbH to PHOENIX group

M1 Kliniken AG announces that its 85% subsidiary, HAEMATO AG, today signed an agreement for the sale of its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe’s leading healthcare providers headquartered in Mannheim. The completion of the transaction remains subject to the customary antitrust approvals. The parties have agreed not to disclose the financial details of the transaction.

With this transaction, M1 Kliniken AG is consistently pursuing its strategic course to position itself as a globally leading, vertically integrated pure-play provider in the field of medical aesthetics.

Contact:
Attila Strauss, Management Board
Corporate Communications
E-Mail: ir@m1-kliniken.de